Retatrutide in Ireland

Short answer

Retatrutide, often shortened to reta, is an investigational triple agonist acting at the GLP-1, GIP and glucagon receptors. As of 5 October 2026, it holds no marketing authorisation in the EU. The laboratory offer is lyophilised material; clinical results apply to the trial medicine and do not automatically establish the properties of a purchased vial.

Why is it always written as reta?

Reta is an informal abbreviation for retatrutide, rather than a separate scientific name. A seller's shorthand does not identify the contents of a particular vial; match its declared material and analytical report.

How does price per milligram work?

Retatrutide is listed in several vial sizes, and comparing headline prices between suppliers is close to meaningless without normalising to price per milligram. Compare every available size: a lower vial price need not mean a lower price per milligram. The table below uses the listed catalogue amounts, not a measured net-content assay for your vial.

A 5 mg vial of retatrutide (reta) costs €40.99, which is €8.20 per milligram. The 30 mg vial is the cheapest per milligram at €4.00.

Availability is confirmed on the fulfilling partner's page before checkout, because stock moves faster than any static page. The full product sheet is on the Retatrutide product page.

What is known about side effects?

Clinical-trial safety data describe the investigational medicine studied under medical supervision; the published phase 2 results are in Jastreboff et al., New England Journal of Medicine 2023; 389: 514-526, doi:10.1056/NEJMoa2301972. They describe the trial medicine, not a reagent sold for laboratory research, and cannot be applied to it. This page gives no guidance for human use.

Where does Retatrutide stand legally in Ireland?

It is an unapproved investigational compound. The Health Products Regulatory Authority (HPRA) authorises medicines in Ireland, and Retatrutide is not on that register - no marketing authorisation has been granted in the EU. The offered material is described for laboratory research, but a research-only label does not decide its legal classification: HPRA assesses a product's presentation, function and other characteristics.

This matters more for Retatrutide than for most compounds, because it belongs to a drug class that does have licensed members. The existence of approved GLP-1 medicines does not extend any approval to Retatrutide. The legal information page sets out the distinction.

What does the certificate show?

The published Retatrutide reports give purity results above 99% for the identified samples. Match the fulfilling supplier, vial size, sample or batch number, test date and method to the selected offer. HPLC area purity and reported peptide quantity are separate results. You can inspect the available documents on the lab reports page before ordering.

Delivery to Ireland

For goods already in free circulation sent from another EU member state to Ireland, there is no ordinary import clearance or import VAT at the border. Seller VAT and delivery charges are separate; product-specific controls still apply. Some shipments to Ireland are currently experiencing delays of 10 days or longer. Allow additional time and confirm the latest delivery estimate with the supplier before ordering.

What is it studied for?

Published work on Retatrutide concerns receptor pharmacology across the three targets and metabolic signalling in preclinical and clinical research models. It is referenced here as research context only. No outcome is claimed, and the compound is not offered for human or veterinary use.